---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-053944"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:42:57.051716+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences acquires TA-ERT for MPS IIIB; BLA submission planned 1H 2026

## Summary
- Acquired exclusive worldwide license for tralesinidase alfa from BioMarin for Sanfilippo Syndrome Type B, a fatal neurodegenerative disease.
- FDA confirmed HS-NRE biomarker may reasonably predict clinical benefit and could support accelerated approval.
- BLA submission for TA-ERT anticipated in first half of 2026; fast-track, orphan, and rare pediatric designations granted.
- Cash and cash equivalents $38.8M as of Dec 31, 2024; expected cash runway through end of 2025.
- 42.2M shares outstanding, 21.4M reserved for warrants and equity as of Dec 31, 2024.

## SEC filing metadata
- accession: 0000950170-25-053944
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017025053944/0000950170-25-053944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017025053944/sprb-20250415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-053944
- JSON: https://secwatch.observer/filing/0000950170-25-053944.json
- Plain text: https://secwatch.observer/filing/0000950170-25-053944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.